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Abstract
The loss of microRNA-122 (miR-122) expression correlates to many characteristic properties of hepatocellular car-
cinoma (HCC) cells, including clonogenic survival, anchorage-independent growth, migration, invasion, epithelial-
mesenchymal transition, and tumorigenesis. However, all of these findings do not sufficiently explain the oncogenic
potential of miR-122. In the current study, we used two-dimensional differential in-gel electrophoresis to measure
changes in the expression of thousands of proteins in response to the inhibition of miR-122 in human hepatoma cells.
Several proteins that were upregulated on miR-122 inhibition were involved in the unfolded protein response (UPR)
pathway. The overexpression of miR-122 resulted in the repression of UPR pathway activation. Therefore, miR-122
may act as an inhibitor of the chaperone gene expression and negatively regulate the UPR pathway in HCC.We further
showed that the miR-122 inhibitor enhanced the stability of the 26S proteasome non-ATPase regulatory subunit 10
(PSMD10) through the up-regulation of its target gene cyclin-dependent kinase 4 (CDK4). This process may activate
the UPR pathway to prevent chemotherapy-mediated tumor cell apoptosis. The current study suggests that miR-122
negatively regulates the UPR through the CDK4-PSMD10 pathway. The down-regulation of miR-122 activated the
CDK4-PSMD10-UPR pathway to decrease tumor cell anticancer drug–mediated apoptosis. We identified a new
HCC therapeutic target and proclaimed the potential risk of the therapeutic use of miR-122 silencing.
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Introduction
The endoplasmic reticulum (ER) is the cellular site of synthesis of
secretory and membrane proteins. These proteins must be properly
folded, which requires the aid of the molecular chaperone proteins
[1,2]. Stress that is caused by hypoxia, nutrient deprivation, or che-
motherapy can lead to an excess of unfolded protein in the ER lumen
of tumor cells. Tumor cells respond to these stresses by activating the
unfolded protein response (UPR), which is a series of signaling cas-
cades that restore a favorable folding environment. Recent data sug-
gest that UPR plays a key role in protecting cancer cells from an
inadequate environment and, therefore, contributes to tumor growth
and survival [3–5].
Hepatocellular carcinoma (HCC) is one of the most prevalent ma-
lignancies and is a leading cause of cancer death worldwide. Eighty
percent of newly developed HCC cases occur in developing
countries; however, the incidence of HCC has increased steadily,
particularly in western countries [6,7]. Despite successful local ther-
apies such as surgery and transcatheter arterial chemoembolization,
patients with HCC develop a high rate of recurrence and metastasis
[8]. Some studies have shown a link between UPR activation and
poor clinical outcomes, and high levels of UPR chaperone expression
correlate to an increasing tumor grade in HCC [6,7]. Furthermore,
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in vitro activation of the UPR pathway alters the sensitivity of tumor
cells to chemotherapeutic agents [4,8]. Oncoprotein proteasome 26S
subunit non-ATPase 10 (PSMD10), which is consistently over-
expressed in HCC [9,10], enhances the activation of the UPR path-
way to promote tumor growth and inhibit apoptosis in HCC cells
[11]. Therefore, understanding UPR pathway activation is of basic
and clinical significance to the treatment of HCC.
The microRNAs (miRNAs) play an important role in the control
of numerous biological processes [12–14]. Growing evidence indi-
cates that miRNAs have a significant role in tumor development
and may constitute robust biomarkers for cancer diagnosis and prog-
nosis [18–21]. MicroRNA-122 (miR-122) is the most abundant
miRNA in the liver, accounting for approximately 70% of the total
miRNA population [15]. Several studies have emphasized the impor-
tance of miR-122 in liver homeostasis [16]. The expression of miR-122
is high in mouse and human hepatocytes but is either silent or very low
in most HCC and transformed cell lines [17–19]. The loss of miR-122
expression correlates to hepatic differentiation phenotype, invasion, and
intrahepatic metastasis [19–21]. More recently, the tumor suppressor
and drug sensitization properties of miR-122 were defined in vitro
and in vivo using nude mice [22,23]. A previous study demonstrated
that miR-122 influenced the sensitivity of HCC cells to doxorubicin
(DOX) through a p53-independent apoptosis pathway [23]. However,
the detailed mechanism by which this phenomenon occurs remains un-
known. Those previous findings do not sufficiently explain the onco-
genic potential of miR-122. New techniques and approaches are
required to study the complex functions of miR-122.
A proteomic approach was successfully used to examine the global
impact of miRNAs on protein output [24,25]. In our current study,
we silenced miR-122 inHuh7 cells, which express a relatively high level
of miR-122 [26]. Differential proteomics results showed that the inhi-
bition of miR-122 in hepatoma cells resulted in the up-regulation of
several molecules involved in the UPR pathway. Importantly, we de-
tected the up-regulation of PSMD10 in Huh7 cells that were trans-
fected with the miR-122 inhibitor. PSMD10 has been shown to
promote recovery from ER stress by upregulating the glucose-regulated
protein 78 (GRP78) and, therefore, may enhance the ER protein fold-
ing capacity in Huh7 cells [11]. Considering the key role of the UPR
pathway in tumor biology [4,27], we performed a thorough mechanis-
tic study of the regulation of the UPR by miR-122. Our findings sug-
gest that the ability of miR-122 to alter tumorigenic properties is at least
partly based on its negative regulation of the UPR pathway.
Materials and Methods
Cell Culture, Treatment, Protein Expression Analysis,
and Viability Assay
Huh7 and HepG2 cells were maintained in modified Eagle medium
and Dulbecco modified Eagle medium, respectively, which were sup-
plemented with 10% fetal calf serum (Gibco, Grand Island, NY) at
37°C in 5% CO2. Huh7 cells were transiently transfected with the
miR-122 inhibitor (Dharmacon, Lafayette, CO) or negative control
RNAs using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) following
the manufacturer’s protocol. After 48 hours, the cells were harvested for
the miR-122 quantitative analysis, the proteomic experiments, or the
Western blot assay. Expression of miR-122 was analyzed using the
TaqMan MicroRNA Assay (Applied Biosystems, Foster City, CA) ac-
cording to the manufacturer’s protocol.
Two-dimensional differential in-gel electrophoresis (DIGE), im-
age analysis, and protein identification were performed as previously
described [25,28].
To assess the cells’ sensitivity to cisplatin (Sigma-Aldrich, St Louis,
MO) or DOX (Tocris Bioscience, Ellisville, MO), cell numbers were
evaluated using a Cell Counting Kit (CCK) 8 (Dojindo, Kumamoto,
Japan) as previously described [28].
Western Blot Analysis and Quantitative Real-time Polymerase
Chain Reaction
Transfected cells were washed twice with phosphate-buffered saline,
resuspended in sample buffer (50 mM Tris-HCl, pH 8.0, 150 mM
NaCl, 0.02% NaN3, 100 μg/L of phenylmethylsulfonyl fluoride,
1 μg/ml of aprotinin, and 1% Triton X-100) and allowed to lyse on
ice for 30 minutes. The lysates were then centrifuged at 16,000g for
30 minutes at 4°C. Protein samples were separated using sodium dodecyl
sulfate–polyacrylamide gel electrophoresis in 12% polyacrylamide gels
and transferred onto nitrocellulose membranes (Amersham Biosciences,
Uppsala, Sweden). Themembranes were then blocked with nonfat milk
and incubated with a 1:5000 dilution of mouse monoclonal antiactin
(Sigma-Aldrich) or 1:500 dilutions of goat anti-PSMD10, GRP78, or
mouse anticalreticulin (CALR), ER protein 29 (ERP29), phospho–
eukaryotic initiation factor 2 α subunit (p-eIF2α), eIF2α, phospho–
inositol-requiring enzyme-1α (p-IRE1α), IRE1α, and cleaved caspase 3
(Santa Cruz Biotechnology, Inc, Santa Cruz, CA). Membranes were
then incubated with 1:10000 dilutions of Irdy680-conjugated goat
antimouse IgG or Irdy800-conjugated rabbit antigoat IgG, and the
bands were detected using an Odyssey infrared scanner (Li-COR,
Lincoln, NE).
The total RNA was isolated from cells using the TRIzol reagent
(Invitrogen) and was reverse-transcribed using SuperScript II reverse
transcriptase and random hexamers (Invitrogen) according to the
manufacturer’s instructions. Subsequently, complementary DNA was
subjected to quantitative real-time polymerase chain reaction (PCR)
using gene-specific primers (Table W1) and StepOne Plus Real-
Time PCR System (Applied Biosystems) following the manufac-
turer’s protocol.
Plasmid Structure, Small Interfering RNAs, and Ectopic
Expression of miR-122 Plasmid Structure
The human pre–miR-122 gene expression plasmid was purchased
from GeneCopoeia (Guangzhou, China). Briefly, the precursor miRNA
expression clone (pEZX–miR-122) was constructed using the vector
pEZX-MR01. The pEZX-MR01 plasmid was used as an empty vector
control. The transcription of the hairpin precursor was driven by an
RNA polymerase III–type promoter. This vector allows for processing
of precursor miRNAs (approximately 150 nucleotides in length) to
generate mature miRNAs using the enzymes involved in the RNAi
machinery. The antibiotic resistance gene was used to select the stable
cell line for further experiments. Stable HCC cell cultures expressing
miR-122 were generated by transfection with the pEZX–miR-122
plasmid followed by antibiotic selection (800 μg/ml of neomycin) for
2 weeks. Stable expression of mature miR-122 was confirmed using
the TaqMan MicroRNA Assay (Applied Biosystems).
The human miR-122 inhibitor expression plasmid (miRZip 122) was
purchased from System Biosciences (San Francisco, CA). Briefly, the
miRZip short hairpin RNAs were cloned into the SBI’s pGreenPuro
shRNA expression lentivector. The miRZip hairpins were designed
to be asymmetrical such that the upper strand of the hairpin does
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not contain the endogenous microRNA sequence, and the lower strand
is preferred for producing antisense microRNAs that are fully comple-
mentary to miR-122. The pGreenPuro shRNA expression lentivector
was used as an empty vector control.
To construct an RNAi expression vector for human PSMD10
(PLKO-shPSMD10), the following oligonucleotides were ligated into
the AgeI-EcoRI site downstream of the U6 promoter of PLKO.1puro:
oligo1 encoding human PSMD10 shRNA1 (shRNA-58073, an annealed
mixture of two DNA oligomers: forward, 5′CCGGTCCGA-
TAAATCCCTGGCTACTACTCGAGTAGTAGCCAGGGATT-
TATCGGTTTTTG3′; and reverse, 5′AATTCAAAAACCGA-
TAAATCCCTGGCTACTACTCGAGTAGTAGCCAGGGATT-
TATCGGA3′), oligo2 encoding human PSMD10 shRNA2 (shRNA-
58074, an annealed mixture of two DNA oligomers: forward, 5′
CCGGTGCTCAAGTGAATGCTGTCAATCTCGAGATTGAC-
AGCATTCACTTGAGCTTTTTG3′; and reverse, 5′AATT-
CAAAAAGCTCAAGTGAATGCTGTCAATCTCGAGATTGA-
CAGCATTCACTTGAGCA3′) and oligo3 encoding human PSMD10
shRNA3 (shRNA-58076, an annealed mixture of two DNA oligomers:
forward, 5′CCGGTCCAGTGAATGATAAAGACGATCTCGA-
GATCGTCTTTATCATTCACTGGTTTTTG3′; and reverse, 5′
AATTCAAAAACCAGTGAATGATAAAGACGATCTCGA-
GATCGTCTTTATCATTCACTGGA3′). The PLKO.1puro plasmid
was used as an empty vector control.
As previously described [10], the small interfering RNA (siRNA)
that specifically targeted PSMD10 (sense strand 5′-GACACUG-
AGGGUAACACUCCUU-3′, antisense strand 5′GGAGUGUUA-
CCCUCCAGUGUCUU-3′), cyclin-dependent kinase 4 (CDK4;
sense strand 5′-AGAUUACUUUGCUGCCUUATT-3′, antisense
strand 5′ UAAGGCAGCAAAGUAAUCUCT-3′), and control siRNAs
(sense strand: 5′-GACCCGCGCCGAGGUGAAGTT-3′) were synthe-
sized by GenePharma (Shanghai, China).
ER Stress Reporter Assay
Transfections were performed using a Lipofectamine 2000 kit
(Invitrogen) according to the manufacturer’s instructions. Control
cells and cells that were stably transfected with miR-122 (1-3 ×
104 cells) were transfected with different reporter plasmids (100 ng per
well) using the Cignal ERSE Reporter kit (SABiosciences, Frederick,
MD). Twenty-four hours after transfection, the cells were treated with
1 μM thapsigargin (TG; Sigma) to modulate the UPR signaling path-
way. The cells were harvested 24 hours after treatment and used to per-
form a dual luciferase assay. The luciferase assay was developed with the
Dual-Luciferase Reporter Assay System (Promega, Madison, WI) ac-
cording to the manufacturer’s instructions.
Assessment of Caspase 3/7 Activity in Cells Stimulated by DOX
Caspase 3 activity was assessed using the ApoONE Homogeneous
Caspase 3/7 Assay (Promega) according to the manufacturer’s instruc-
tions. Cells were cultured in 96-well culture dishes to 50% to 70%
confluence. To induce cell apoptosis, cells were treated with DOX
(1 μg/ml). Caspase 3/7 activity was analyzed after a 24-hour incubation.
3′ Untranslated Region Constructs and Luciferase Assay
The 3′ untranslated region (UTR) of CDK4 containing an intact
miR-122 recognition sequence was amplified by PCR using genomic
DNA. The PCR product was subcloned into a pGL3 promoter vec-
tor (Promega) immediately downstream of the luciferase gene. The
primers used were as follows: forward, 5′-CCCAAGCTTCATGTG-
GAGTGTTGGCTGTATC-3′; and reverse, 5′-GACTAGTGGA-
AAGGGACAAGAGGGAAC-3′. Cells were seeded into 24-well
plates and cotransfected with 0.5 μg of the respective pmiR-3′UTR
construct and 0.05 μg of the pRL-TK vector (Promega) using the
Lipofectamine 2000 kit (Invitrogen). The pRL-TK vector was used
as an internal control. After 48 hours, the luciferase activity was mea-
sured using the Dual-Luciferase Reporter Assay System (Promega).
Nude Mouse HCC Model
All of the mice used in this experiment received humane care. To
image tumor chemosensitivity in mice, Huh7 cells were transfected with
pCMV-Luciferase (Promega) and selected with neomycin (800 μg/ml).
Five million of these cells were injected into the flanks of nude mice, and
tumor cell activity was monitored using the IVIS Lumina II system (Cal-
iper Life Sciences, Hopkinton, MA) 5 minutes after intraperitoneal injec-
tion of 4.0 mg of luciferin (Gold Biotech, St Louis, MO) in 50 μl of saline.
The pEZX-miR-122 HepG2 tumors were established by intra-
dermally injecting 5 × 106 tumor cells in 80 μl of minimum essential
medium into the back flanks of female nude mice (day 0). Tumor
sizes were measured every 5 days using a slide caliper.
Terminal Deoxynucleotidyl Transferase-Mediated
Deoxyuridine Triphosphate Nick-end Labeling Assay
The extent of hepatocyte apoptosis was detected using the termi-
nal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate
nick-end labeling (TUNEL) assay. TUNEL-positive cells were counted
using the random selection of high-power fields (400×) distributed
over six independent sections. The numbers of TUNEL-positive and
TUNEL-negative cells were compiled.
Statistical Analysis
The results are expressed as mean ± SD of the mean. The compar-
isons between the groups were performed using the Student’s t test
or the analysis of variance test as appropriate. The reported P values
were two-sided and were considered significant when less than .05.
Results
Up-regulation of ER Stress Chaperone Proteins in Huh7 Cells
That Are Transfected with the miR-122 Inhibitor
The novel proteomic methods allowed us to detect interaction
mechanisms among a wider scope of targets [24,29]. In the current
study, we transiently transfected Huh7 cells with the miR-122 inhibi-
tor and control RNA. The suppressive effect of the miR-122 inhibitor
was demonstrated using TaqMan real-time PCR, which showed that
the expression level of miR-122 was decreased by 72% in the Huh7
cells that were transfected with the miR-122 inhibitor (Figure 1A).
Two-dimensional DIGE was used to observe differences in protein
expression between miR-122 inhibitor–transfected and control RNA-
transfected Huh7 cells. After DIGE, the Cy2, Cy3, and Cy5 channels
of each gel were individually imaged for each gel, and the images were
analyzed using DeCyder 5.0 software (GEHealthcare, Uppsala, Sweden).
The intensity values of 2153 protein spots were measured (Figure 1B). To
identify proteins that were differentially expressed between the miR-122
inhibitor–transfectedHuh7 cells and control RNA–transfectedHuh7 cells,
we performed a Kruskal-Wallis test and applied the Bonferroni adjust-
ment. We selected the protein spots that had a Bonferroni-adjusted P <
.01 and a greater than 1.3-fold change between the control- and
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miR-122 inhibitor–transfected cells. Thirty-three protein spots met these
criteria. Mass spectrometry identified 19 unique proteins (Table W2)
corresponding to the 33 protein spots. The functional classification ac-
cording to Gene Ontology (www.geneontology.org) demonstrated that
multiple identified proteins (4/19 proteins) were ER-localized or ER
stress–associated proteins (Table W2). Other proteins were involved
in DNA binding, protein binding, catalytic activity and structural mol-
ecule activity. The expression of the ER stress chaperones calreticulin
(CALR), ER protein 29 (ERP29) and SET were increased when miR-
122 was inhibited (Figure 1C). Interestingly, we also demonstrated that
PSMD10, which enhanced the ER folding capacity and promoted
recovery from ER stress through GRP78 [11], was overexpressed in
miR-122 inhibitor–transfected Huh7 cells (Figure 1C and Table W2).
Ectopic Overexpression of miR-122 in HepG2 Cells
and the Suppression of the UPR
To further examine the relationships among miR-122, UPR, and
HCC, we generated a model of miR-122 up-regulation in HepG2
cells, which do not express miR-122 [26]. Stably expressing pEZX–
miR-122 clones were identified using TaqMan real-time PCR (Fig-
ure 2A). The miR-122 expression level of clone 1 was increased 32-fold
compared to that in HepG2 cells that were transfected with pEZX con-
trol plasmids. The HepG2–miR-122 clone 1 cells were used in subse-
quent experiments.
To investigate whether the expression of miR-122 affected the ex-
pression of other ER stress markers in the presence of the ER stress
inducer TG, the expression of GRP78, p-eIF2α, and p-IRE1α was
significantly decreased in HepG2–miR-122 cells (Figure 2B). In ad-
dition, the mRNA expression of GRP78 and CHOP was significantly
decreased in HepG2–miR-122 cells compared to that in the HepG2–
control cells at every time point after TG addition (Figure 2C ). These
results suggest that the ectopic expression of miR-122 negatively reg-
ulates the expression of important ER stress chaperones.
To further observe the effect of miR-122 on ER stress in vitro, the
Cignal ERSE Reporter kit was used to monitor the ER stress response.
The luciferase activity was decreased in miR-122 mimic–transfected
HepG2 cells (Figure 2D, left) and in HepG2 cells that stably over-
expressed miR-122 (Figure 2D, right). These results further demon-
strate that miR-122 represses the UPR pathway.
miR-122 Inhibitor Enhances PSMD10 Stability through
Its Target Gene CDK4
We selected PSMD10 for further study based on the several con-
siderations. First, our proteomic results suggest that miR-122 may
regulate the UPR pathway. In addition, a recent study reported that
Figure 1. Down-regulation of miR-122 in Huh7 cells and the differentially expressed protein spots displayed in two-dimensional DIGE
images. (A) Huh7 cells were transiently transfected with the miR-122 inhibitor or the control RNA. After 48 hours, the transfected cells
were harvested for real-time PCR analysis of the miR-122 expression. Values indicate the 72% reduction of miR-122 expression in miR-
122 inhibitor–transfected Huh7 cells compared to that in the control cells. (B) The extracted proteins were labeled with fluorescent dyes
and separated using DIGE. The numbered spots indicate the differentially expressed protein spots. (C) CALR, SET, ERP29, and PMSD10
were overexpressed when the miR-122 was inhibited in Huh7 cells. Western blot analysis was used to assess the expression level of
the four proteins. A representative blot (left) and the numeric data obtained from the densitometry analysis of the blots (right; n = 4)
are shown.
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Figure 2. Screening of HepG2 cells that stably overexpressing miR-122 and the ER stress reporter assay. (A) The expression level of miR-
122 was measured in stably transfected clones. Clone 1, which displayed a 32-fold increase in the miR-122 expression, had the highest
miR-122 expression level. Clone 1 was used as a stable miR-122–overexpressing HepG2 cell line throughout the study. (B) Western blot
analysis was used to assess the protein expression of GRP78, p-eIF2α, and p-IRE1α in HepG2–miR-122 cells (clone 1) compared to that
in HepG2–control cells at 24 hours after TG addition. A representative blot (left), and the numeric data obtained from the densitometry
analysis of the blots (right; n = 4) are shown. (C) The mRNA expression of GRP78 (left) and CHOP (right) was significantly decreased in
HepG2–miR-122 cells (clone 1) compared to that in HepG2–control cells (negative control) at every time point after TG addition. (D) For
the ER stress reporter assay, miR-122 mimic–transfected HepG2 cells (1-3 × 104 cells) were transfected with different reporter plasmids
(100 ng per well) using the Cignal ERSE Reporter kit at 6 hours after mimic transfection. Other experiment procedures were performed
as described in Materials and Methods. The luciferase activity was decreased in miR-122 mimic–transfected HepG2 cells (left) and clone
1 cells (right). All data represent the mean values ± SD from experiments performed at least five times.
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PSMD10 enhanced the UPR and upregulated GRP78 expression
[11]. Second, PSMD10 interacts with a predicted target gene of
miR-122 called CDK4 [9]. Third, PSMD10 is consistently over-
expressed in HCC, promotes tumor growth and inhibits apoptosis
in HCC cells [9,10].
PSMD10 is an ankyrin-repeat oncoprotein that interacts with
CDK4 [9], which is a miR-122–predicted target gene. We first val-
idated whether CDK4 was a target gene of miR-122. The 3′UTR of
CDK4 contains a putative miR-122 binding site (Figure 3A). To test
whether the predicted binding sites in CDK4 mRNA could mediate
repression of translation by miR-122, the 3′UTR of CDK4 was sub-
cloned downstream of the luciferase gene in the pGL3 control vector.
This construct was assayed in HEK293T cells transfected with a miR-
122 mimic. As shown in Figure 3B, cells that were transfected with the
reporter construct containing the 3′UTR of CDK4 had significantly
lower luciferase activity after the cells cotransfected with the miR-122
mimic compared to cells that were cotransfected with control RNA.
To confirm the results of the 3′UTR reporter assay, the expression of
CDK4 was assessed in Huh7 cells that were transfected with the miR-
122 inhibitor and in HepG2 cells that were transfected with miR-122
mimics using Western blot analysis. CDK4 was decreased in miR-122
mimic–transfected HepG2 cells (Figure 3C ) or in stable miR-122–
expressing HepG2 cells (Figure 3D) and increased in miR-122 inhibitor–
transfected Huh7 cells (Figure 3E). Results of the Western blot assays
Figure 3. CDK4 was confirmed as a target of miR-122. (A) The miR-122 binding site in the 3′UTR of CDK4 is shown. (B) The verification of
binding site specificity is shown. The reduction of the luciferase activity that was driven by the CDK4-3′UTR construct was observed in
cells transfected with miR-122 mimic. (C, D, and E) The negative regulation of CDK4 by miR-122 was demonstrated using Western blot
analysis. These results indicates that the protein expression of CDK4 is inhibited in miR-122 mimic–transfected HepG2 cells (C), stable
miR-122–expressing HepG2 cells (D) and is increased in the miR-122 inhibitor–transfected Huh7 cells (E). The expression of PSMD10
was also changed based on the level of miR-122. The representative blots (left) and numeric data obtained from densitometry analysis of
the blots (right, n = 4) are shown.
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confirmed the 3′UTR reporter assay results. Furthermore, the changes
in the expression of PSMD10 correlated to the changes in the expres-
sion of CDK4.
We did not detect up-regulation of PSMD10 transcription after
miR-122 was inhibited in Huh7 cells (data not shown). To detect
whether the miR-122 inhibitor enhanced PSMD10 stability, we
treated miR-122–repressed Huh7 cells with the protein synthesis in-
hibitor cycloheximide (CHX) or the proteasome inhibitor MG-132.
As shown in Figure 4A, only MG-132 abolished the up-regulation of
PSMD10 protein levels in miR-122 inhibitor–treated Huh7 cells. A
time course detection of PSMD10 degradation after CHX addition
was performed to determine whether there was more initial total
PSMD10 protein or whether PSMD10 degraded more slowly. As
shown in Figure 4B, the protein level of PSMD10 between the miR-
122 inhibitor– and negative control-transfected Huh7 cells was different
at 24 hours after CHX addition. This difference could also be detected
at 36 hours but not 6 or 12 hours after CHX addition. This finding
indicates that the miR-122 inhibitor enhances PSMD10 stability.
We supposed that miR-122 might enhance PSMD10 stability
through CDK4. We performed a Western blot analysis to examine
the protein level of PSMD10 in miR-122–repressed Huh7 cells that
were treated with siRNAs against CDK4. As shown in Figure 4C ,
PSMD10 protein levels were decreased after the treatment with
CDK4 siRNAs. These results indicate that the up-regulation of the
miR-122 target gene CDK4 is essential for PSMD10 accumulation
in miR-122 inhibitor–treated Huh7 cells.
miR-122 Negatively Regulates the UPR through
the CDK4-PSMD10 Chaperone Pathway
A recent study reported that PSMD10 enhanced the UPR and up-
regulated GRP78 expression [11]. Therefore, we further investigated
whether PSMD10 was involved in the miR-122–mediated negative
Figure 4. The miR-122 inhibitor enhanced the PSMD10 stability through its target gene CDK4. (A) At 24 hours after the miR-122 inhibitor
and the negative control were transfected, Huh7 cells were incubated with the protein synthesis inhibitor cycloheximide (CHX, 0.5 μg/μl)
or the proteasome inhibitor MG-132 (5 μM) for another 24 hours. The protein expression of PSMD10 was detected using Western blot
analysis. MG-132 treatment but not CHX treatment abolished the change in the expression of PSMD10 in miR-122 inhibitor– and neg-
ative control-transfected cells. (B) At 6 hours after the miR-122 inhibitor and the negative control were transfected, Huh7 cells were
incubated with CHX (0.5 μg/μl) for another 6, 12, 24, or 36 hours. The protein expression of PSMD10 was detected using Western blot
analysis. (C) siRNA against CDK4 abolished the increased PSMD10 protein expression in miR-122 inhibitor–transfected Huh7 cells (n = 4).
(D) PSMD10 siRNA decreased GRP78 protein expression in miR-122 inhibitor–transfected Huh7 cells (n = 4). (E) The miR-122 inhibitor and
PSMD10 siRNA–cotransfected Huh7 cells were treated as described in Figure 2D. The results from the ER stress reporter assay show that
the luciferase activity is decreased in miR-122 inhibitor–transfected Huh7 cells transfected with PSMD10 siRNA (n = 4). For Western blot
analysis, the relative ratios after normalization are shown below each panel.
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regulation of the UPR. We used a Cignal ERSE Reporter kit to mon-
itor the activity of the ER stress response in miR-122 inhibitor–treated
Huh7 cells that were also knocked down for PSMD10 expression. The
luciferase activity was decreased in cells that were also knocked down
for PSMD10 expression (Figure 4D). GRP78 expression was also dra-
matically reduced in miR-122 inhibitor–treated Huh7 cells when
PSMD10 expression was knocked down (Figure 4E). Based on these
findings, we concluded that the miR-122 inhibitor increased the UPR
at least partly by upregulating PSMD10.
PSMD10 Is Associated with the Proapoptotic Role
of miR-122 In Vitro and In Vivo
Considering that the UPR is an adaptive response that increases
cell survival under stress conditions, we further explored whether the
CDK4-PSMD10-UPR pathway played a key role in drug resistance.
We treated miR-122–repressed Huh7 cells with cisplatin or DOX
and measured the cell survival using a CCK-8 kit and the chemother-
apeutic agent–triggered apoptosis using a caspase 3 activity assay. Cells
that were transfected with the miR-122 inhibitor displayed lower levels
of apoptosis in response to cisplatin (Figure 5, A and B). This result
was confirmed using a gain-of-function analysis, which showed that
miR-122 enhanced the sensitivity of HepG2 cells to cisplatin or
DOX (data not shown). We next investigated whether siRNAs against
PSMD10 could enhance the chemosensitivity of Huh7 cells that were
transfected with the miR-122 inhibitor. In the miR-122 inhibitor–
transfected Huh7 cells, reduced expression of PSMD10 resulted in a
significant increase in DOX-triggered apoptosis (Figure 5, C and D).
Taken together, the results of gain- and loss-of-function studies imply
that the miR-122 inhibitor may reduce the sensitivity of HCC cells to
chemotherapeutic agent–induced apoptosis and that PSMD10 may
play an important role in this process.
To further confirm the in vitro experiment results, we generated a
human miR-122 inhibitor expression plasmid (miRZip–miR-122) and
an RNAi expression vector for human PSMD10 (shRNA-PSMD10).
We next evaluated the effect of the miR-122–PSMD10 pathway on
chemosensitivity of Huh7 cells using an in vivo model. Stable cell lines
expressing firefly luciferase were injected into the flanks of nude mice
(four mice for each treatment group). After the tumors were established
(day 0), each plasmid (100 μg of a plasmid in 80 μl of PBS) was injected
intratumorally on days 0 and 2. On days 3 and 6, 6 mg/kg of DOX
was intravenously injected through the tail vein. On days 6, 9, and 12,
the mice were imaged. The effectiveness of miRZip–miR-122 and
Figure 5. PSMD10 mediated miR-122 inhibitor–induced drug resistance. (A) Western blot detection of cleaved caspase 3 is shown.
Twenty-four hours after Huh7 cells were transfected with the miR-122 inhibitor or the control, Huh7 cells were incubated with cisplatin
(8 μg/ml) for another 24 hours. C-Caspase3 indicates cleaved caspase 3 (n = 4). (B) The relative live cell number was determined using
the CCK-8 assay (mean ± SD). Huh7 cells were incubated with different concentrations of cisplatin for another 24 hours after transfection
with the miR-122 inhibitor or the control (n = 4). (C) Caspase 3/7 activity was detected using an ApoONE Homogeneous Caspase 3/7
Assay. Twenty-four hours after Huh7 cells were cotransfected with the miR-122 inhibitor and siRNA against PSMD10 or respective con-
trol, Huh7 cells were stimulatedwith DOX (1 μg/ml) for another 24 hours. (D) Relative live cell number was determined by way of CCK-8 assay.
Twenty-four hours after Huh7 cells were transfected with the miR-122 inhibitor, siRNA against PSMD10 or their respective controls. Huh7
cells were stimulated with different concentrations of DOX for another 24 hours. siRNA, siRNA against PSMD10; Control indicates the
corresponding negative control for miR-122 inhibitor; NC, the corresponding negative control for siRNA against PSMD10. (For 0.2 μg/ml,
miR-122 inhibitor + NC vs controls + NC [P = .032], miR-122 inhibitor + siRNA vs controls + NC [P = .56]; for 0.8 μg/ml, miR-122 inhibitor +
NC vs controls + NC [P = .028], miR-122 inhibitor + siRNA vs controls + NC [P = .82]; n = 4).
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shRNA-PSMD10 were examined by real-time PCR using the tumor
tissues that were implanted in nude mice. As shown in Figure 6A, miR-
Zip–miR-122 and shRNA-PSMD10 had an effect on their respective
targets after being injected into nude mice. The quantification of the
luciferase signal showed that PSMD10 shRNA (shRNA-PSMD10
plasmid) abolished the miR-122 inhibitor–induced drug resistance
in vivo (Figure 6B). Representative photographs of tumors in nudemice
are shown in Figure 6C .
Discussion
MicroRNAs are posttranscriptional modulators of gene expression
and play an important role in many developmental and metabolic
processes [12]. Many studies have shown that miR-122 inhibited
many characteristic properties of cancer cells, including clonogenic
survival, anchorage-independent growth, migration, invasion, epithelial-
mesenchymal transition, and tumorigenesis in nude mice [22]. More
recently, a study revealed that miR-122 regulated mitochondrial metab-
olism and that its loss might contribute to the morbidity and mortality
of liver cancer [30]. Although many identified targets of miR-122 are
involved in differentiation, cell cycle progression, invasion, metastasis,
and tumorigenesis, the relationships between the different functions
and miR-122 targets remain to be elucidated in a broader perspective.
More importantly, some studies have found that miRNA secondary tar-
gets and downstream pathways may form a more sensitive measure of
miRNA function than the direct measurements of miRNA expression
levels or miRNA target genes [30,31]. Proteomics, which was an ap-
proach that can simultaneously analyze multiple proteins changes, is
used to scan the miRNA secondary targets and downstream pathways.
Figure 6. Tumor chemotherapy in nude mice. Tumor establishment, plasmids, and DOX injection were performed as described in the
main text. (A) The effectiveness of the plasmids miRZip–miR-122 and shRNA-PSMD10 was examined by real-time PCR using tumor
tissues implanted in nude mice. (B) The relative luciferase signal captured in each tumor at different time points is shown (n = 4). On
days 6, 9, and 12 after the intratumorally injection of plasmid, the mice were imaged using IVIS Lumina II System as described inMaterials
and Methods. (C) Photographs of tumors that developed in mice were obtained by imaging with the IVIS system. The representative of
luciferase signal (ROI) was captured in each group at day 9 after the plasmid injection. The most effective RNAi expression vector for
human PSMD10, shRNA-PSMD10, was used.
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Recently, many new proteomic approaches have been applied to miRNA
research [24,25,29,32]. In the current study, we inhibited the expression
of miR-122 in Huh7 cells and identified differentially expressed proteins
using DIGE. Our results show that four of these proteins are known
UPR-related proteins (Table W1 and Figure 1, B and C). CALR is an
ER chaperone that acts in the proper folding of many proteins and gly-
coproteins through the calreticulin/calnexin cycle [33]. ERP29 is widely
thought to be a folding assistant for secretory proteins and probably func-
tions as a protein disulfide isomerase-like molecular chaperone [34].
Some studies have shown that SET-mediated dephosphorylation of
BCL-2 is required to protect BCL-2 from proteasome-dependent degra-
dation, which affects the resistance to ER stress [35], PSMD10, which is
consistently overexpressed in HCC, has been shown to promote tumor
growth and inhibit apoptosis in HCC cells by enhancing the UPR and
upregulating GRP78 expression [11]. Therefore, we speculated that
miR-122 affected hepatocarcinogenesis and apoptosis through UPR.
For further confirmation of the effect of miR-122 on ER chaperones
and UPR, we screened stable HepG2 cell clones that overexpressed
miR-122 (Figure 2A). Results from the assays using the ERSE reporter,
which contains binding sites for the transcription factors NF-Y/CBF
and YY1, show that miR-122 overexpression decreases the activity of
the UPR pathway (Figure 2, C and D). More importantly, our results
demonstrate that expressions of important ER stress chaperones,
GRP78 and CHOP, are repressed by the overexpression of miR-122
after TG stimulation. GRP78, which is a member of the highly con-
served Hsp70 protein family, is constitutively expressed and is upregu-
lated on UPR activation [36]. Increased expression of GRP78 enhances
the protein folding capacity of the ER and is associated with prosurvival
responses [37]. The repression of the UPR by miR-122 may decrease
the protein folding capacity of the ER and plays a proapoptotic role in
carcinoma cells. Given that phosphorylated eIF2α inhibits translation
initiation thus promoting global attenuation of protein translation, this
study suggests that miRNA-122 has a dual role in translational control.
This inference is in accordance with previous reports that described
how miR-122 acted as a tumor suppressor gene for hepatocarcinogen-
esis [19,20,22].
PSMD10 contains six ankyrin repeats and interacts with CDK4 and
the S6 ATPase of the 26S proteasome [9]. To elucidate the mechanism
by which miR-122 negative regulated the UPR pathway, we predicted
the target genes of miR-122 and identified these target genes using a 3′
UTR reporter assay (Figure 3, A and B). The regulation of CDK4
expression by miR-122 was validated in miR-122 mimic transfected
HepG2 cells (Figure 3C ), stable miR-122–expressing HepG2 cells
(Figure 3D), and miR-122 inhibitor–transfected Huh7 cells (Figure 3E).
Interestingly, our results indicate that the up-regulation of the miR-122
target gene CDK4 is essential for the PSMD10 accumulation in miR-
122 inhibitor–treated Huh7 cells (Figure 4C). A recent study provided
evidence that PSMD10 protected HCC cells from ER stress–induced
apoptosis through the enhancement of UPR signaling [11]. Therefore,
we hypothesized that PSMD10 was a key link between miR-122 and
UPR signaling. Indeed, our results indicate that PSMD10 is at least
partly responsible for the increased expression of GRP78 and UPR sig-
naling on inhibition of miR-122 (Figure 4, D and E).
With respect to cancer, many aspects of the UPR pathway are cyto-
protective and help cancer cells to withstand the stress that is caused by
hypoxia, nutrient deprivation, or anticancer treatment. Activation of
the UPR pathway might promote dormancy, aid tumor growth, or alter
tumor chemosensitivity. In the current study, we found that down-
regulation of miR-122 in Huh7 cells increased the expression of
PSMD10 and subsequently enhanced UPR signaling. The effect of
the miR-122–PSMD10-UPR pathway on antitumor drug–associated
apoptosis was also examined in vitro and in vivo. In summary, this
pathway plays key roles in drug resistance (Figures 5 and 6). First,
miR-122 inhibitor enhanced the drug tolerance of p53 mutant
Huh7 cells (Figure 5, A and B). More importantly, siRNAs against
PSMD10 increased anticancer drug–mediated apoptosis in miR-122–
repressed Huh7 cells (Figures 5, C andD, and 6). A previous study dem-
onstrated that the miR-122/cyclin G1 interaction affected the DOX
sensitivity of HCC cells by mediating p53 activity [23]. Furthermore,
the same study showed that miR-122 also influenced the sensitivity of
HCC cells to DOX through a p53-independent apoptosis pathway
[23]; however, the mechanism by which this phenomenon occurred is
unknown. Therefore, our findings expand on these results: we may have
identified the miR-122–PSMD10-UPR pathway as the p53-independent
apoptosis pathway observed in the previous study [23].
When injected into nude mice, tumor cells can grow under stressed
microenvironments such as those caused by ischemia, hypoxemia, or
nutrient deprivation. Tumor growth was inhibited in our miR-122–
overexpressing HepG2 cells, and the percentage of cells undergoing
apoptosis was increased in miR-122–overexpressing tumors compared
to that in control tumors (Figure W1). Understanding the relationships
among miR-122, UPR, and apoptosis will be helpful to reveal the
molecular mechanisms involved in hepatocarcinogenesis and to identify
novel therapeutic targets.
In summary, we have clearly demonstrated that miR-122 negatively
regulates UPR chaperones and we have identified a miR-122–
PSMD10-UPR pathway, both of which support the potential applica-
tion of miR-122 in HCC chemotherapy.
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Results
Studies have shown that overexpression of miR-122 suppresses in situ
tumor formation. To study the role of miR-122 in tumor formation in
our model, nude mice were injected with HepG2–miR-122 or HepG2–
control cells. The tumor volume in mice that were injected with
HepG2–miR-122 cells was smaller than that in mice that were injected
with the HepG2–control cells (Figure W1, A and B). We further exam-
ined apoptosis in mice that were injected with each tumor type. The
TUNEL results show that the frequency of apoptotic cells is significantly
increased in HepG2–miR-122 tumors (Figure W1, C and D).
Table W1. Real-time PCR Primers.
Gene Sequence Product Size (bp)
GRP78 5′CCGTCCTATGTCGCCTTCACT3′ 231
5′TGTCTTTGTTTGCCCACCTCC3′
CHOP 5′CCACTCTTGACCCTGCTTCTC3′ 172
5′TGACCACTCTGTTTCCGTTTC3′
PSMD10 5′GGGGCTAATCCAGATGCTA3′ 207
5′ACTTGCTCCTTGGGACACC3′
GAPDH 5′ CGGATTTGGTCGTATTGGG 3′ 208
5′ CTGGAAGATGGTGATGGGATT 3′
Table W2. Differential Expression Proteins between miR-122 Inhibitors and Controls Transfected Huh7 Cells Identified by MALDI-TOF MS.
Master
Spot ID*
Fold Change† Accession No.‡ Name and Official Symbol Coverage and
Protein Score§
Molecular Function Subcellular Location
635 2.2 gi|62897681 Calreticulin, CALR 26%/176 Ca(2+) binding, regulation of
gene transcription
Endoplasmic reticulum lumen
505 2.01 gi|15149465 Caldesmon 1, CALD1 25%/263 Ca(2+) binding Thin filaments
Stress fibers
695 1.96 gi|4502551 Calumenin, CALU 55%/516 Protein folding and sorting Endoplasmic reticulum lumen
948 1.95 gi|5803013 ER protein 29, ERP29 29%/90 Processing of secretory proteins
within the ER
Endoplasmic reticulum lumen
806 1.86 gi|55663125 SET nuclear oncogene, SET 18%/167 Multitasking protein, involved in apoptosis,
transcription, nucleosome assembly,
and histone binding
Cytoplasm
Endoplasmic reticulum
Nucleus
960 1.69 gi|46249388 Phosphoserine phosphatase, PSPH 32%/129 Catalyzes the last step in the biosynthesis
of serine from carbohydrates
—
977 1.63 gi|23065552 Glutathione S -transferase
mu 3 (brain), GSTM3
46%/216 Conjugation of reduced glutathione
to a wide number of exogenous and
endogenous hydrophobic electrophiles
Cytoplasm
1015 1.62 gi|4506217 Proteasome (prosome, macropain)
26S subunit, non-ATPase,
10 PSMD10
23%/276 Acts as a regulatory subunit of the 26S
proteasome which is involved in the
ATP-dependent degradation of
ubiquitinated proteins
Proteasome
861 1.59 gi|16198390 glyoxalase domain containing 4,
GLOD4
30%/148 Inhibit the HCC cell growth Mitochondrion
748 0.80 gi|1000094 Centromere protein F,
350/400ka (mitosin), CENPF
14%/73 Required for kinetochore function
and chromosome segregation in mitosis
Cytoplasm, perinuclear region
1013 −0.69 gi|4885417 Ubiquitin-conjugating enzyme
E2K (UBC1 homolog, yeast),
UBE2K
40%/219 Catalyzes the covalent attachment
of ubiquitin to other proteins
Cytoplasm
654 −0.53 gi|30311 Keratin 18, KRT18 26%/78 Involved in the uptake of
thrombin-antithrombin
complexes by hepatic cells
Cytoplasm, perinuclear region
632 −0.7 gi|307086 Keratin 10, KRT10 21%/118 Cytokeratin —
631 −0.69 gi|9836652 Chromosome 20 open reading
frame 3, C20orf3
37%/78 Exhibits strong arylesterase activity with
beta-naphthyl acetate and phenyl acetate
Membrane
884 −0.68 gi|1705694 Cytochrome c-type heme lyase
(CCHL), HCCS
22%/86 Links covalently the heme group to the
apoprotein of cytochrome c
Mitochondrion inner membrane
1302 −0.66 gi|24475861 Phosphohistidine phosphatase 1,
PHPT1
44%/186 EDTA-insensitive phosphohistidine
phosphatase
Cytoplasm
664 −0.59 gi|38570107 EF-hand calcium binding
domain 6, EFCAB6
20%/66 Negatively regulates the androgen receptor Nucleus
709 −0.56 gi|62896663 Annexin A7, ANXA7 33%/292 Calcium/phospholipid-binding protein
which promotes membrane fusion
and is involved in exocytosis
Membrane binding
744 −0.49 gi|4502923 Calponin 3, acidic, CNN3 28%/74 Thin filament–associated protein —
*Master spot ID is the unique master number that refers to the labels in Figure 1B.
†Fold change presents the ratio of miRNA-122 inhibitors to controls.
‡Accession no. is the MASCOT results of MALDI-TOF/TOF searched from the NCBInr database.
§Coverage (%) means the number of amino acids spanned by the assigned peptides divided by the sequence length. Protein score (based on combined MS and MS/MS spectra). The proteins had
statistically significant protein score of great than 64 (P ≤ .05) were considered successfully identified.
Figure W1. Subcutaneous tumors in nude mice. (A) The effects of miR-122 overexpression on subcutaneous tumors in nude mice. The
arrows indicate the morphology of the tumors from the injected site. (B) In vivo subcutaneous tumor growth curves of stably transfected
miR-122 or control HepG2 cells (n = 5, *P < .05). The subcutaneous tumors were examined every five days after cell injection. Note that
tumors that are induced by miR-122–transfected HepG2 cells are significantly reduced in size compared to that in the control. (C) The
TUNEL results showed that the frequency of apoptotic cells is significantly increased in HepG2–miR-122 tumors. One of the represen-
tative fields is shown. (D) The number of TUNEL-positive cells per field was calculated (n = 5, *P < .05).
